Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
MOIO
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- NCT05078047 ↗
- Active, not recruiting
- UNICANCER
- Deep
We haven't built an HCP commentary report on MOIO (reduced dose intensity of IO in Lung Cancer Metastatic) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MOIO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 47 | |
| Bluesky threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Cancer Metastatic; Renal Cell Carcinoma; Head and Neck Cancer; Triple Negative Breast Cancer; Merkel Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Urothelial Carcinoma; Colorectal Carcinoma With Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Endometrial Carcinoma; Cervical Cancer; Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma; Basal Cell Carcinoma; Squamous Skin Carcinoma
- Interventions
- Reduced dose intensity of IO
- Arms
- Experimental arm · Experimental
- Control arm · No intervention
- Enrollment
- 646 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- UNICANCER
- Start
- Mar 8, 2022
- Primary completion
- May 7, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05078047 · updated Jul 17, 2026
Publications
linked from the registry- Gravis G, Marino P, Olive D, Penault-LLorca F, Delord JP, Simon C, Lamrani-Ghaouti A, Sabatier R, Ciccolini J, Boher JM. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study. BMC Cancer. 2023 May 2;23(1):393. doi: 10.1186/s12885-023-10881-8. PubMed 37131154